Kawaguchi G, Hildebrand W H, Hiraiwa M, Karaki S, Nagao T, Akiyama N, Uchida H, Kashiwase K, Akaza T, Williams R C
Department of Tumor Biology, Tokyo University Hospital, University of Tokyo, Japan.
Immunogenetics. 1992;37(1):57-63. doi: 10.1007/BF00223545.
Newly defined antigens of the B5, B35 cross-reacting group have been found in Japanese and North American Indians. Nucleotide sequencing of the alleles encoding the Japanese B5.35 antigen and the variant B5 antigen from the Piman Indians show them to be identical. This new allele, B5102, differs from B5101 by a single nucleotide substitution that changes residue 171 from histidine to tyrosine. Residue 171, which is part of the alpha 2 helix, is believed to contribute directly to peptide interaction in the A pocket of the binding groove and is either histidine or tyrosine in all HLA-A, B, C heavy chains. Tyrosine 171 is shared by B5102, B3501, B3502, and B5301 and must be responsible for the serological cross-reactivities of these molecules not shared with B5101. Stimulation of lymphocytes from a B5101 positive donor with B5102 positive cells failed to generate cytotoxic T cells with specificity for the difference between these molecules. However, one out of five clones of cytotoxic T cells raised against B5101 failed to lyse targets expressing B*5102. Substitution of histidine for tyrosine at residue 171 affected recognition of HLA-B35-restricted human minor histocompatibility antigen-specific T cell clones.
在日本人和北美印第安人中发现了B5、B35交叉反应组的新定义抗原。对编码日本B5.35抗原和皮马印第安人变体B5抗原的等位基因进行核苷酸测序,结果显示它们是相同的。这个新等位基因B5102与B5101的区别在于一个单核苷酸替换,该替换将第171位残基从组氨酸变为酪氨酸。第171位残基是α2螺旋的一部分,被认为直接参与结合槽A口袋中的肽相互作用,并且在所有HLA - A、B、C重链中要么是组氨酸要么是酪氨酸。酪氨酸171存在于B5102、B3501、B3502和B5301中,必定是这些分子与B5101不共有的血清学交叉反应的原因。用B5102阳性细胞刺激来自B5101阳性供体的淋巴细胞,未能产生对这些分子之间差异具有特异性的细胞毒性T细胞。然而,针对B5101产生的五个细胞毒性T细胞克隆中有一个未能裂解表达B*5102的靶细胞。将第171位残基的酪氨酸替换为组氨酸影响了对HLA - B35限制性人类次要组织相容性抗原特异性T细胞克隆的识别。